CEL-SCI Receives U.S. Patent on Pre-Sensitizing Cancer Prior to Treatment

CEL-SCI has been issued a U.S. patent, titled "A Method of Pre-Sensitizing Cancer Prior to Treatment With Radiation and/or Chemotherapy and a Novel Cytokine Mixture," covering its cancer drug, Multikine.

This invention relates to a breakthrough method for presensitizing cancer with Multikine prior to a therapeutic treatment, such as chemotherapy, radiation therapy or immunotherapy. CEL-SCI's drug Multikine is effective in inducing cancerous cells' entry into the cell cycle phase thereby increasing their vulnerability to treatment.